[Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer]

Bull Cancer. 2021 Jun;108(6):562-563. doi: 10.1016/j.bulcan.2021.04.003. Epub 2021 May 20.

[Article in French]

Authors

Baudouin Courtier¹, Thomas Pierret²

Affiliations

¹ Hôpital-Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France.
² CHU de Grenoble-Alpes, oncologie thoracique, 1, boulevard de la Chantourne, 38700 La-Tronche, France. Electronic address: tpierret@chu-grenoble.fr.

PMID: 34023064
DOI: 10.1016/j.bulcan.2021.04.003

No abstract available

Keywords: Cancer du poumon; Lung cancer; Metastases; Métastases; RET; Targeted therapies; Thérapies ciblées.

Publication types

News

MeSH terms

Adenocarcinoma of Lung / drug therapy
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / secondary
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Approval
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Proto-Oncogene Proteins c-ret / genetics*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyridines / adverse effects
Pyridines / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Pyrazoles
Pyridines
Pyrimidines
pralsetinib
selpercatinib
Proto-Oncogene Proteins c-ret
RET protein, human